Streck_CD-Chex CD117_200Streck Inc, Omaha, Ne, has announced the addition of CD25 and CD71 markers for CD-Chex CD117 Plus, the only commercially available positive procedural control for CD117. CD-Chex 117 Plus eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, CD25, and CD71, saving time and money. The control was developed with characteristics similar to the abnormal peripheral blood leukocytes often found in a hematolymphoid neoplastic patient sample. It also possesses surface CD117, CD25, and CD71 that are detectable with fluorescent monoclonal antibodies by flow cytometry. Abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties and a low level of CD45 expression. CD-Chex CD117 Plus features 30-day open-vial stability and 90-day closed-vial stability. For more information, visit Streck.